Antibiotice Past Earnings Performance
Past criteria checks 5/6
Antibiotice has been growing earnings at an average annual rate of 20%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 10.8% per year. Antibiotice's return on equity is 9.6%, and it has net margins of 13.2%.
Key information
20.0%
Earnings growth rate
20.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 10.8% |
| Return on equity | 9.6% |
| Net Margin | 13.2% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump
Jan 30
We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease
Jan 13These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely
Aug 16Is Antibiotice (BVB:ATB) A Risky Investment?
Jun 08These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively
Mar 10Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield
Feb 11Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)
Jan 12Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 16
Is Antibiotice (BVB:ATB) Using Too Much Debt?
Nov 24Revenue & Expenses BreakdownBeta
How Antibiotice makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 615 | 81 | 162 | 0 |
| 30 Sep 23 | 597 | 86 | 168 | 0 |
| 30 Jun 23 | 564 | 67 | 155 | 0 |
| 31 Mar 23 | 548 | 52 | 161 | 0 |
| 31 Dec 22 | 505 | 51 | 131 | 0 |
| 30 Sep 22 | 498 | 41 | 126 | 0 |
| 30 Jun 22 | 467 | 45 | 136 | 0 |
| 31 Mar 22 | 440 | 35 | 127 | 0 |
| 31 Dec 21 | 379 | 30 | 126 | 0 |
| 30 Sep 21 | 394 | 27 | 126 | 0 |
| 30 Jun 21 | 366 | 27 | 124 | 0 |
| 31 Mar 21 | 342 | 26 | 122 | 0 |
| 31 Dec 20 | 347 | 26 | 118 | 0 |
| 30 Sep 20 | 357 | 27 | 117 | 0 |
| 30 Jun 20 | 370 | 28 | 112 | 0 |
| 31 Mar 20 | 403 | 32 | 108 | 0 |
| 31 Dec 19 | 395 | 31 | 108 | 0 |
| 30 Sep 19 | 371 | 35 | 102 | 0 |
| 30 Jun 19 | 385 | 37 | 102 | 0 |
| 31 Mar 19 | 375 | 34 | 100 | 0 |
| 31 Dec 18 | 369 | 34 | 97 | 0 |
| 30 Sep 18 | 348 | 34 | 87 | 0 |
| 30 Jun 18 | 351 | 34 | 89 | 0 |
| 31 Mar 18 | 344 | 32 | 82 | 0 |
| 31 Dec 17 | 339 | 34 | 79 | 0 |
| 30 Sep 17 | 344 | 33 | 82 | 0 |
| 30 Jun 17 | 341 | 33 | 68 | 0 |
| 31 Mar 17 | 338 | 29 | 68 | 0 |
| 31 Dec 16 | 337 | 30 | 67 | 0 |
| 30 Sep 16 | 343 | 30 | 69 | 0 |
| 30 Jun 16 | 345 | 28 | 72 | 0 |
| 31 Mar 16 | 336 | 28 | 73 | 0 |
| 31 Dec 15 | 334 | 27 | 72 | 0 |
| 30 Sep 15 | 321 | 25 | 59 | 0 |
| 30 Jun 15 | 305 | 28 | 74 | 0 |
| 31 Mar 15 | 314 | 32 | 69 | 0 |
| 31 Dec 14 | 322 | 31 | 69 | 0 |
| 30 Sep 14 | 320 | 34 | 59 | 0 |
| 30 Jun 14 | 327 | 32 | 55 | 0 |
| 31 Mar 14 | 321 | 32 | 58 | 0 |
| 31 Dec 13 | 320 | 31 | 59 | 0 |
| 30 Sep 13 | 305 | 18 | 110 | 0 |
| 30 Jun 13 | 287 | 19 | 89 | 0 |
Quality Earnings: ATB has high quality earnings.
Growing Profit Margin: ATB's current net profit margins (13.2%) are higher than last year (10.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATB's earnings have grown significantly by 20% per year over the past 5 years.
Accelerating Growth: ATB's earnings growth over the past year (57.5%) exceeds its 5-year average (20% per year).
Earnings vs Industry: ATB earnings growth over the past year (57.5%) exceeded the Pharmaceuticals industry 3%.
Return on Equity
High ROE: ATB's Return on Equity (9.6%) is considered low.